Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Medicinal Chemistry
  4. Fast Track Articles
  5. Fast Track Article
image of Design and Development of [1,2,4]Triazolo[4,3-b][1,2,4]triazines as Potential Anticancer Agents with Genotoxicity and Apoptotic Activity

Abstract

Aims: In this current study, a new series of triazolo-triazine derivatives were designed and synthesized as potential anticancer agents. Methods: The antiproliferative activity of the new compounds was evaluated against three different cancerous cell lines (MDA-MB-231, HCT-116, A549, and HT-29) using an MTT assay. To evaluate the mechanism of action, the ability of the best compound in apoptosis induction and DNA damage was evaluated using the flow cytometry technique and comet assays. Furthermore, molecular docking simulation was used to investigate their interactions with the two targets, VEGFR2 and c-Met kinases. Results: Results showed that 6-(4-bromophenyl)-3-((4-methoxybenzyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine () demonstrated the best anti-proliferative activity against the human colorectal carcinoma cells HCT-116 with an IC value of 38.7 ± 1.7 µM. evaluations showed that the triazolo-triazine scaffold, along with the methoxy substitution of compound was involved in creating effective H-bond interactions in the active site of both targets. Conclusion: Our results showed that compound significantly increased cell death through apoptosis induction and caused a significant increase in genotoxicity. Furthermore, it was found that the tested compound , with a selectivity index of 1.74, possessed selective antiproliferative activity towards the colorectal cancer cell line HCT-116 compared to the normal fibroblast cell line. These findings could be useful in the development of novel VEGFR2/c-Met dual-targeted inhibitors in the future.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mc/10.2174/0115734064327919240926112444
2024-10-09
2025-03-07

  • From This Site

    /content/journals/mc/10.2174/0115734064327919240926112444
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Torre L.A. Siegel R.L. Ward E.M. Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol. Biomarkers Prev. 2016 25 1 16 27 10.1158/1055‑9965.EPI‑15‑0578 26667886
    [Google Scholar]
  2. Morgan E. Arnold M. Gini A. Lorenzoni V. Cabasag C.J. Laversanne M. Vignat J. Ferlay J. Murphy N. Bray F. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut 2023 72 2 338 344 10.1136/gutjnl‑2022‑327736 36604116
    [Google Scholar]
  3. Xi Y. Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021 14 10 101174 10.1016/j.tranon.2021.101174 34243011
    [Google Scholar]
  4. Xiao Z. Morris-Natschke S.L. Lee K.H. Strategies for the optimization of natural leads to anticancer drugs or drug candidates. Med. Res. Rev. 2016 36 1 32 91 10.1002/med.21377 26359649
    [Google Scholar]
  5. van der Zanden S.Y. Qiao X. Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 2021 288 21 6095 6111 10.1111/febs.15583 33022843
    [Google Scholar]
  6. Xie J. Zhang X. Meng D. Li Y. Deng P. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening. J. Biomol. Struct. Dyn. 2024 42 3 1249 1267 10.1080/07391102.2023.2199082 37042992
    [Google Scholar]
  7. Rusinov V.L. Charushin V.N. Chupakhin O.N. Biologically active azolo-1,2,4-triazines and azolopyrimidines. Russ. Chem. Bull. 2018 67 4 573 599 10.1007/s11172‑018‑2113‑8
    [Google Scholar]
  8. Buchanan S.G. Hendle J. Lee P.S. Smith C.R. Bounaud P.Y. Jessen K.A. Tang C.M. Huser N.H. Felce J.D. Froning K.J. Peterman M.C. Aubol B.E. Gessert S.F. Sauder J.M. Schwinn K.D. Russell M. Rooney I.A. Adams J. Leon B.C. Do T.H. Blaney J.M. Sprengeler P.A. Thompson D.A. Smyth L. Pelletier L.A. Atwell S. Holme K. Wasserman S.R. Emtage S. Burley S.K. Reich S.H. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther. 2009 8 12 3181 3190 10.1158/1535‑7163.MCT‑09‑0477 19934279
    [Google Scholar]
  9. Heinrich M.C. Jones R.L. von Mehren M. Schöffski P. Serrano C. Kang Y.K. Cassier P.A. Mir O. Eskens F. Tap W.D. Rutkowski P. Chawla S.P. Trent J. Tugnait M. Evans E.K. Lauz T. Zhou T. Roche M. Wolf B.B. Bauer S. George S. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): A multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 21 7 935 946 10.1016/S1470‑2045(20)30269‑2 32615108
    [Google Scholar]
  10. Bhide R.S. Cai Z.W. Zhang Y.Z. Qian L. Wei D. Barbosa S. Lombardo L.J. Borzilleri R.M. Zheng X. Wu L.I. Barrish J.C. Kim S.H. Leavitt K. Mathur A. Leith L. Chao S. Wautlet B. Mortillo S. Jeyaseelan R. Sr Kukral D. Hunt J.T. Kamath A. Fura A. Vyas V. Marathe P. D’Arienzo C. Derbin G. Fargnoli J. Discovery and preclinical studies of ( R )-1-(4-(4-Fluoro-2-methyl-1 H -indol-5-yloxy)-5- methylpyrrolo[2,1- f ][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem. 2006 49 7 2143 2146 10.1021/jm051106d 16570908
    [Google Scholar]
  11. Cui J.J. Shen H. Tran-Dubé M. Nambu M. McTigue M. Grodsky N. Ryan K. Yamazaki S. Aguirre S. Parker M. Li Q. Zou H. Christensen J. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats. J. Med. Chem. 2013 56 17 6651 6665 10.1021/jm400926x 23944843
    [Google Scholar]
  12. Dadashpour S. Küçükkılınç T.T. Ayazgök B. Hosseinimehr S.J. Chippindale A.M. Foroumadi A. Irannejad H. Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors. Future Med. Chem. 2019 11 10 1119 1136 10.4155/fmc‑2018‑0412 31280674
    [Google Scholar]
  13. Khatir Z.Z. Di Sotto A. Percaccio E. Tuylu Kucukkilinc T. Ercan A. Chippindale A.M. Valipour M. Irannejad H. 4‐3‐[(Pyridin‐4‐ylmethyl)amino]‐[1,2,4]triazolo[4,3‐ b ][1,2,4]triazin‐6‐ylphenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator. Arch. Pharm. 2024 357 6 2300704 10.1002/ardp.202300704 38442326
    [Google Scholar]
  14. Guo Y. Peng X. Ji Y. Zhang Y. Ding J. Zhan Z. Ai J. Duan W. Synthesis of triazolotriazine derivatives as c-Met inhibitors. Mol. Divers. 2021 25 2 839 846 10.1007/s11030‑020‑10067‑5 32157572
    [Google Scholar]
  15. Chen F. Wang Y. Ai J. Zhan Z. Lv Y. Liang Z. Luo C. Mei D. Geng M. Duan W. O-linked triazolotriazines: Potent and selective c-Met inhibitors. ChemMedChem 2012 7 7 1276 1285 10.1002/cmdc.201200145 22539497
    [Google Scholar]
  16. Grozav A. Găină L. Pileczki V. Crisan O. Silaghi-Dumitrescu L. Therrien B. Zaharia V. Berindan-Neagoe I. The synthesis and antiproliferative activities of new arylidene-hydrazinyl-thiazole derivatives. Int. J. Mol. Sci. 2014 15 12 22059 22072 10.3390/ijms151222059 25470024
    [Google Scholar]
  17. Lv P.C. Li D.D. Li Q.S. Lu X. Xiao Z.P. Zhu H.L. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Bioorg. Med. Chem. Lett. 2011 21 18 5374 5377 10.1016/j.bmcl.2011.07.010 21802290
    [Google Scholar]
  18. dos Santos Silva T.D. Bomfim L.M. da Cruz Rodrigues A.C.B. Dias R.B. Sales C.B.S. Rocha C.A.G. Soares M.B.P. Bezerra D.P. de Oliveira Cardoso M.V. Leite A.C.L. Militão G.C.G. Anti-liver cancer activity in vitro and in vivo induced by 2-pyridyl 2,3-thiazole derivatives. Toxicol. Appl. Pharmacol. 2017 329 212 223 10.1016/j.taap.2017.06.003 28610992
    [Google Scholar]
  19. Sharma P. Srinivasa Reddy T. Thummuri D. Senwar K.R. Praveen Kumar N. Naidu V.G.M. Bhargava S.K. Shankaraiah N. Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents. Eur. J. Med. Chem. 2016 124 608 621 10.1016/j.ejmech.2016.08.029 27614408
    [Google Scholar]
  20. Gomha S.M. Abdelaziz M.R. Kheder N.A. Abdel-aziz H.M. Alterary S. Mabkhot Y.N. A facile access and evaluation of some novel thiazole and 1,3,4-thiadiazole derivatives incorporating thiazole moiety as potent anticancer agents. Chem. Cent. J. 2017 11 1 105 10.1186/s13065‑017‑0335‑8 29086869
    [Google Scholar]
  21. Wolf J. Seto T. Han J.Y. Reguart N. Garon E.B. Groen H.J.M. Tan D.S.W. Hida T. de Jonge M. Orlov S.V. Smit E.F. Souquet P.J. Vansteenkiste J. Hochmair M. Felip E. Nishio M. Thomas M. Ohashi K. Toyozawa R. Overbeck T.R. de Marinis F. Kim T.M. Laack E. Robeva A. Le Mouhaer S. Waldron-Lynch M. Sankaran B. Balbin O.A. Cui X. Giovannini M. Akimov M. Heist R.S. GEOMETRY mono-1 Investigators Capmatinib in MET exon 14–mutated or MET-amplified non–small-cell lung cancer. N. Engl. J. Med. 2020 383 10 944 957 10.1056/NEJMoa2002787 32877583
    [Google Scholar]
  22. Zhan Z. Peng X. Liu Q. Chen F. Ji Y. Yao S. Xi Y. Lin Y. Chen T. Xu Y. Ai J. Geng M. Duan W. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b ][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. Eur. J. Med. Chem. 2016 116 239 251 10.1016/j.ejmech.2016.03.076 27061987
    [Google Scholar]
  23. Valipour M. Naderi N. Heidarli E. Shaki F. Motafeghi F. Talebpour Amiri F. Emami S. Irannejad H. Design, synthesis and biological evaluation of naphthalene-derived (arylalkyl)azoles containing heterocyclic linkers as new anticonvulsants: A comprehensive in silico, in vitro, and in vivo study. Eur. J. Pharm. Sci. 2021 166 105974 10.1016/j.ejps.2021.105974 34390829
    [Google Scholar]
  24. Tutty M.A. Vella G. Vennemann A. Wiemann M. Prina-Mello A. Evaluating nanobiomaterial-induced DNA strand breaks using the alkaline comet assay. Drug Deliv. Transl. Res. 2022 12 9 2243 2258 10.1007/s13346‑022‑01178‑7 35612707
    [Google Scholar]
  25. Al-Musawi S. Hadi A.J. Hadi S.J. Hindi N.K.K. Preparation and characterization of folated chitosan-magnetic nanocarrier for 5-fluorouracil drug delivery and studying its effect in bladder cancer therapy. J. Glob. Pharma Technol. 2019 11 628 637
    [Google Scholar]
  26. Njiojob C.N. Rhinehart J.L. Bozell J.J. Long B.K. Synthesis of enantiomerically pure lignin dimer models for catalytic selectivity studies. J. Org. Chem. 2015 80 3 1771 1780 10.1021/jo502685k 25584871
    [Google Scholar]
  27. Marchand P. Antoine M. Gerlach M. Günther E. Schuster T. Czech M. Seipelt I. A convenient synthesis of novel 2, 8-disubstituted pyrido [3, 4-b] pyrazines possessing biological activity. Synthesis 2012 44 1 69 82 10.1055/s‑0031‑1289613
    [Google Scholar]
  28. Dadashpour S. Küçükkılınç T.T. Ercan A. Hosseinimehr S.J. Naderi N. Irannejad H. Synthesis and anticancer activity of benzimidazole/benzoxazole substituted triazolotriazines in hepatocellular carcinoma. Anti-Cancer Agents Med Chem 2019 19 2120 2129
    [Google Scholar]
  29. Collins A.R. The comet assay for DNA damage and repair: Principles, applications, and limitations. Mol. Biotechnol. 2004 26 3 249 261 10.1385/MB:26:3:249 15004294
    [Google Scholar]
  30. Aghajanshakeri S. Salmanmahiny A. Aghajanshakeri S. Babaei A. Alishahi F. Babayani E. Shokrzadeh M. Modulatory effect of amifostine (WR-1065) against genotoxicity and oxidative stress induced by methotrexate in human umbilical vein endothelial cells (HUVECs). Toxicol. Mech. Methods 2023 33 9 755 765 10.1080/15376516.2023.2238069 37537746
    [Google Scholar]
  31. Aghajanshakeri S. Ataee R. Karami M. Aghajanshakeri S. Shokrzadeh M. Cytomodulatory characteristics of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) against cypermethrin on skin fibroblast cells (HFF-1). Toxicology 2023 499 153655 10.1016/j.tox.2023.153655 37871686
    [Google Scholar]
/content/journals/mc/10.2174/0115734064327919240926112444
Loading
Design and Development of [1,2,4]Triazolo[4,3-b][1,2,4]triazines as Potential Anticancer Agents with Genotoxicity and Apoptotic Activity
Bentham Science Publishers ; https://doi.org/10.2174/0115734064327919240926112444
/content/journals/mc/10.2174/0115734064327919240926112444
/content/journals/mc/10.2174/0115734064327919240926112444
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: VEGFR2 ; DNA damage ; c-Met ; Anticancer ; apoptosis ; triazolo-triazine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test